# Phase 3 Safety and Efficacy Study of I.V. Iclaprim v Linezolid in cSSSI (ASSIST-1)

> **NCT00299520** · PHASE3 · COMPLETED · sponsor: **Arpida AG**

## Conditions studied

- Complicated Skin and Skin Structure Infection

## Interventions

- **DRUG:** intravenous iclaprim or intravenous linezolid

## Key facts

- **NCT ID:** NCT00299520
- **Lead sponsor:** Arpida AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** —
- **Final completion:** 2006-07
- **Target enrollment:** — (—)
- **Last updated:** 2008-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00299520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00299520, "Phase 3 Safety and Efficacy Study of I.V. Iclaprim v Linezolid in cSSSI (ASSIST-1)". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00299520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*